This study from Japan included 100 patients with localized prostate cancer treated with moderately hypofractionated PT (70 GyRBE in 28 fractions) for evaluation. Of the 100 patients, 15 were classified as low risk, 43 as intermediate risk, and 42 as high risk. With a median follow-up of 96 months, this study reported the 5-year biochemical recurrence free rate was 99%. The 5-year cumulative incidences of grades 1 and 2 GI adverse events were 9% and 1%. No grade ≥3 GI was observed. The 5-year cumulative incidences of grades 1 and 2 GU adverse events were 41% and 4%. No grade ≥3 GU reported.